Sentences with phrase «of bladder cancer patients»

The effect of raw and cooked broccoli consumption on survival rates of bladder cancer patients.

Not exact matches

Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66 % of patients.

Researchers say further study is needed using individual patient - level data among men with high risk prostate cancer to assess the benefit of HRT and whether treatment toxicity, particularly those to the bladder and urinary system are also low with HRT.

Although self - appraisal of overall well - being may mediate physiologic responses to surgery, patient - reported health status has not been extensively studied among bladder cancer patients to date, and its utility in predicting postoperative outcomes, such as complications, has not been previously examined.»

Michael A. Johnson and colleagues at the University of Kansas wanted to investigate how carboplatin therapy — commonly given to patients with breast, bladder, colon and other cancers — affects dopamine and serotonin.

Studies have shown that the drug alvimopan significantly accelerates recovery of gastrointestinal function and shortens the hospital stay for patients undergoing gastrointestinal or bladder cancer surgery.

In one of the new papers, Zitvogel's group examined data for 249 lung, kidney, and bladder cancer patients, 69 of whom took antibiotics for routine reasons such as dental work or a urinary tract infection before or soon after starting a PD - 1 drug.

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.

It represents a real advance in the second - line treatment of advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these patients.

In the current study, organoids were made from the tumor cells of 22 patients with invasive bladder cancer.

The current standard of care for patients with bladder cancer that has not invaded muscle is surgery to remove the tumor plus immunotherapy or chemotherapy.

Columbia University Irving Medical Center (CUIMC) and NewYork - Presbyterian researchers have created patient - specific bladder cancer organoids that mimic many of the characteristics of actual tumors.

«In almost one - third of patients, bladder cancer detection is late.

«Physicians who care for patients with a history of uterine cancer and pelvic radiation treatment should keep in mind the increased risk of bladder cancer,» said Dr. Wu.

Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer.

It is commonly thought that bladder cancers that develop after pelvic radiation tend to be aggressive, with high grades and stages, but this study found that the types, grades, and stages of bladder cancer that developed were similar in patients treated with and without radiation therapy.

The findings indicate the importance of monitoring patients for potential signs of bladder cancer to ensure early diagnosis and treatment.

Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented today at the 2013 Clinical Congress of the American College of Surgeons.

With an average follow - up of 15 years, bladder cancer incidence in uterine cancer patients treated with pelvic radiation therapy was twice as high as that seen in patients treated without radiation.

A University of Colorado Cancer Center study published in the journal Oncogene used next - generation sequencing technologies to perform the most detailed DNA - based analysis to date of 25 commonly used bladder cancer cell lines, allowing researchers to match patient tumors with their closest genetic cell line match, and demonstrated genetic alterations that may make cells more or less sensitive to common therCancer Center study published in the journal Oncogene used next - generation sequencing technologies to perform the most detailed DNA - based analysis to date of 25 commonly used bladder cancer cell lines, allowing researchers to match patient tumors with their closest genetic cell line match, and demonstrated genetic alterations that may make cells more or less sensitive to common thercancer cell lines, allowing researchers to match patient tumors with their closest genetic cell line match, and demonstrated genetic alterations that may make cells more or less sensitive to common therapies.

«This is really an important finding, because before patients and their doctors decide to pursue active surveillance as a management option for prostate cancer, both the physician and patient should agree on a follow - up schedule to closely monitor the cancer,» said Chamie, who is surgical director of UCLA's bladder cancer program and a member of the Jonsson Comprehensive Cancer Ccancer, both the physician and patient should agree on a follow - up schedule to closely monitor the cancer,» said Chamie, who is surgical director of UCLA's bladder cancer program and a member of the Jonsson Comprehensive Cancer Ccancer,» said Chamie, who is surgical director of UCLA's bladder cancer program and a member of the Jonsson Comprehensive Cancer Ccancer program and a member of the Jonsson Comprehensive Cancer CCancer Center.

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Ccancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer CCancer Center.

A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd - IFN / Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer

Kato said the patient whose bladder cancer grew out of control after receiving atezolizumab was «very intelligent, very knowledgeable.»

or doctors at the University of California, San Diego, it was seemingly a no - lose proposition: A 73 - year - old patient's bladder cancer was slowly progressing but he was generally stable and strong.

Michael O'Donell reports on the efficacy of the combination of interferon - alpha 2b plus low dose BCG in patients with BCG refractory bladder cancer.

Since then, however, other researchers have observed the same gene fusion in a percentage of lung, esophageal, breast, head and neck, cervical, and bladder cancers, affecting tens of thousands of cancer patients overall.

April 21, 2018 - Administration of simultaneous chemotherapy and immunotherapy might be a safe, viable option for some patients with metastatic bladder cancer, according to recent research published in European Urology.

A systematic review of observational studies suggested that smoking cessation after bladder cancer is beneficial, but owing to confounding and methodological concerns of included studies no firm conclusions could be drawn.30 Some observational studies have also shown an association between smoking cessation in patients with head and neck cancer and reduced risk of disease progression and mortality, but the absence of a systematic review and meta - analysis means that the strength of this association is uncertain.31 32 33

Also impressive were the results of Genentech's anti-PD-L1 antibody, MPDL3280A, in patients with urinary bladder cancer (UBC).

In a study involving 12 patients with bladder cancer, who also underwent prostate surgery as part of their treatment, she identified the ICOS molecule as the first immunologic marker identified in both tumor tissues and the systemic circulation that can be used as a biomarker for monitoring of anti-CTLA-4 treated patients as a possible marker of therapeutic activity.

A total of 13 Dream Team clinical trials are active right now, for patients with bladder cancer, kidney cancer, prostate cancer, triple - negative breast cancer, gastric cancer, pancreatic cancer, small cell and non-small cell lung cancer, sarcoma, and melanoma, and seven more trials are planned.

Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer in early 2017.

Miniature versions of bladder cancers could help physicians identify personalized treatment options for patients.

As a result, patients may require multiple procedures before their bladder is fully rid of bladder cancer.

As a result, European guidelines for the management of bladder cancer have recommended that urologists use it to ensure that their patients have optimal care.

In these cases, UroSEEK could be detecting clonal proliferations in the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population Risques and Kennedy, 2018Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepancies.

In my acupuncture and Traditional Chinese Medicine (TCM) practice, I help countless patients manage the side effects of prostate cancer treatment, and many other men's health issues like bladder problems, Chronic Prostatitis (CP) and Chronic Pelvic Pain Syndrome (CPPS).

A 49 - year - old male bladder cancer patient opted for vitamin C treatment administered intravenously instead of radiotherapy or chemotherapy.

One of the approaches we currently follow in the Bladder Cancer Clinic is to allow patients to add on to the schedule on short notice, if we can possibly accommodate them.

A recent study that can be found in the Journal of the National Cancer Institute is the latest one to find that diabetes drugs with thiazolidinedione is linked to a two to three times greater risk of developing bladder cancer than if the patient were to take a diabetes medication with sulfonyCancer Institute is the latest one to find that diabetes drugs with thiazolidinedione is linked to a two to three times greater risk of developing bladder cancer than if the patient were to take a diabetes medication with sulfonycancer than if the patient were to take a diabetes medication with sulfonylurea.

If a patient has a prior history of bladder cancer, they should use the drug with caution, carefully weighing the advantages of controlling blood glucose against the possible risk of cancer recurrence.

If it is proven that the drug's manufacturers put their desire for profit ahead of patient safety, an Actos user who develops bladder cancer or cardiovascular disease may be able to pursue compensation for their injuries.

Since Takeda Pharmaceuticals has failed to perform important early research and warn patients about Actos» health risks, thousands of patients may have already developed bladder cancer or experienced a heart attack because of the drug.

Despite the payout, Takeda U.S.A, refused to take the dangerous drug off of the market, even though the drug was banned in Germany and France years ago after a study released in 2012 found that the drug caused an 83 % percent increased risk of the patient developing bladder cancer.

They also found that Actos users with type II diabetes that were taking the drug for the first time had an 83 % greater risk of developing bladder cancer than other patients.

According to McGill University researchers in Montreal, an evaluation of over 115,000 patients found that taking Actos for more than two years doubles the bladder cancer risk.

Although Actos has been available to diabetes users in the US for a number of years, it was just last year that the Food and Drug Administration put out a Drug Safety Communication giving notification that the medication's label had been revised to include a warning that use of the drug for over a year dramatically increases the chances that the patient might develop bladder cancer.

One of the reasons for this is that we represent diabetes patients (and their families) that have developed bladder cancer after taking the medication Actos.

It wasn't until 2011 that the US Food and drug Administration issued a safety communication notifying the public that Actos's label had finally been modified to come with the warning that using the medication for longer than a year may significantly increase a patient's chances of getting bladder cancer.